- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about BIIB
Recent news which mentions BIIB
Can the government’s new ability to negotiate drug prices eliminate blockbuster price tags?
February 08, 2023
From MarketWatch
Sage Therapeutics-Biogen Partnered Depression Candidate Under Priority FDA Review, Analyst Says Its 'Incrementally Positive'
February 06, 2023
From Benzinga
New Alzheimer’s drug shows some promise, but has big price tag
February 02, 2023
From MarketWatch
The 7 Most Undervalued Nasdaq Stocks to Buy in February 2023
February 01, 2023
From InvestorPlace
From Benzinga
7 CRISPR Stocks With the Best Long-Term Potential
January 30, 2023
From InvestorPlace
From Motley Fool
Why the FDA didn’t grant an approval to Lilly’s Alzheimer’s drug
January 20, 2023
From MarketWatch
Tech Stocks Get Netflix Boost Amid Jittery Wider Market On Friday, Dow Stares At 4th Straight Loss
January 20, 2023
From Benzinga
From Benzinga
$100 Invested In Biogen 20 Years Ago Would Be Worth This Much Today
January 19, 2023
Tickers
BIIB
From Benzinga
From Motley Fool
Tickers
BIIB
From Motley Fool
Neurodegenerative Diseases Focused Company Goes Public Via Wilbur Ross-Backed SPAC, Joins Alzheimer's Race To Compete Biogen
January 18, 2023
From Benzinga
This Monumental Breakthrough Could Turn the World Upside Down -- and Make Some Investors Filthy Rich
January 17, 2023
From Motley Fool
1 Hot Growth Stock to Buy Now, and 1 to Avoid
January 11, 2023
From Motley Fool
From Motley Fool
Barron's Top Weekend Stock Picks: Tesla, Snowflake, Delta And Why Warren Buffett's Berkshire Hathaway May Be In For Big Tax Bill
January 07, 2023
From Benzinga
From Benzinga
From Benzinga
FDA approves treatment for people with mild forms of Alzheimer’s
January 06, 2023
From MarketWatch
From Benzinga
Lecanemab Alert: What Would Alzheimer’s Drug Approval Mean for Biogen (BIIB) Stock?
January 06, 2023
From InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
January 06, 2023
From Benzinga
1 Stock Defying the Downturn to Buy, and 1 to Avoid
January 06, 2023
From Motley Fool
Could Eli Lilly Stock Help You Become a Millionaire?
January 05, 2023
From Motley Fool
Amid criticism for its handling of another Alzheimer’s drug, FDA will decide this week whether to approve lecanemab
January 03, 2023
From MarketWatch
1 Large-Cap Biotech Stock to Buy for 2023 and Beyond
January 03, 2023
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.